Remove Clinical Trials Remove Compliance Remove Safety
article thumbnail

Cannabis Standards Rely on Transparency, Compliance and Collaboration

Cannabis Law Report

This “zero recall” standard, the team said, was attributed to the fact that their cannabis product standards with regard to food safety and health was high and involved documentation of over 100 pages. . o Respondent checks: Age gates are in place to ensure compliance, and if underaged, then medical licenses must be checked.

article thumbnail

MAPS: Regulatory Publishing Specialist – Remote Position Regulatory Affairs · Any City, Any State, California

Cannabis Law Report

The individual in this position supports global regulatory programs, projects, and compliance initiatives across regions and business units. Preference for background in biological or data science (such as: Computer Science, Neuroscience, Cognitive Sciences, Data Science, or a similar field) with a strong interesting in clinical research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

‘Too costly, not enough evidence it works’, says UK in blow to cannabis campaigners

Cannabis Law Report

However, health professionals have been reluctant to prescribe cannabis-based medicines in the UK because of the lack of clinical trial evidence of its benefits and safety. This would answer questions about safety and efficacy, they said. The final guideline is expected to be published in November 2019.

article thumbnail

How Medical Marijuana Helps With Multiple Sclerosis Symptoms

MMJ Recs

By reducing the need for multiple medications with potentially conflicting side effects, medical marijuana can simplify treatment regimens and improve patient compliance. Some clinical trials have shown that cannabinoids, particularly THC and CBD, effectively reduce muscle spasticity and pain in MS patients.

Marijuana 111
article thumbnail

Press Release: PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications

Cannabis Law Report

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

article thumbnail

Guest Post: Denmark’s pilot pharma trial attracts first-movers

Cannabis Law Report

Pharma-grade cannabis is scarce in the world and Denmark has quickly stepped in to fill the niche, cultivating to EU GACP standards, adhering to patient safety, retailing in pharmacies, tracking every medical cannabis prescription, and making patient access affordable. The roadmap ahead includes clinical trials and more research in Denmark.

article thumbnail

Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

Cannabis Law Report

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS